Brief: Aptinyx Reports Results From Phase 2B Study Of Nyx-2925 In Painful Diabetic Peripheral Neuropathy

Aptinyx

07/04/2022 12:16

April 7 (Reuters) - Aptinyx Inc  APTX.O :
    * APTINYX REPORTS RESULTS FROM PHASE 2B STUDY OF NYX-2925 IN
PAINFUL DIABETIC PERIPHERAL NEUROPATHY
    * APTINYX INC - NYX-2925 DID NOT ACHIEVE PRIMARY ENDPOINT OF
STUDY
    * APTINYX INC - NYX-2925 DID NOT ACHIEVE STATISTICALLY
SIGNIFICANT
SEPARATION FROM PLACEBO ON STUDY'S PRIMARY ENDPOINT
    * APTINYX INC - DETAILED DATA FROM STUDY CONTINUE TO BE
EVALUATED.
    * APTINYX INC - SEPARATION BETWEEN NYX-2925 AND PLACEBO WAS
ALSO
NOT OBSERVED ON OTHER PAIN ENDPOINTS

Source text for Eikon:  ID:nBwbFGNdWa 
Further company coverage:  APTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))